Literature DB >> 26093897

Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer.

Da-Qiang Li1, Rakesh Kumar2.   

Abstract

Since the initial recognition of the metastasis-associated protein 1 (MTA1) as a metastasis-relevant gene approximately 20 years ago, our appreciation for the complex role of the MTA family of coregulatory proteins in human cancer has profoundly grown. MTA proteins consist of six family members with similar structural units and act as central signaling nodes for integrating upstream signals into regulatory chromatin-remodeling networks, leading to regulation of gene expression in cancer cells. Substantial experimental and clinical evidence demonstrates that MTA proteins, particularly MTA1, are frequently deregulated in a wide range of human cancers. The MTA family governs cell survival, the invasive and metastatic phenotypes of cancer cells, and the aggressiveness of cancer and the prognosis of patients with MTA1 overexpressing cancers. Our discussion here highlights our current understanding of the regulatory mechanisms and functional roles of MTA proteins in cancer progression and expands upon the potential implications of MTA proteins in cancer biology and cancer therapeutics.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Gene transcription; Metastasis-associated gene; NuRD complex

Mesh:

Substances:

Year:  2015        PMID: 26093897     DOI: 10.1016/bs.acr.2015.04.005

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  14 in total

Review 1.  Signaling coupled epigenomic regulation of gene expression.

Authors:  R Kumar; S Deivendran; T R Santhoshkumar; M R Pillai
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

2.  Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells.

Authors:  H Marzook; S Deivendran; B George; G Reshmi; T R Santhoshkumar; R Kumar; M R Pillai
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

3.  Interplay between 15-lipoxygenase-1 and metastasis-associated antigen 1 in the metastatic potential of colorectal cancer.

Authors:  S Tunçer; S Tunçay Çağatay; A G Keşküş; M Çolakoğlu; Ö Konu; S Banerjee
Journal:  Cell Prolif       Date:  2016-06-19       Impact factor: 6.831

Review 4.  Structure, expression and functions of MTA genes.

Authors:  Rakesh Kumar; Rui-An Wang
Journal:  Gene       Date:  2016-02-09       Impact factor: 3.688

Review 5.  SIX3 function in cancer: progression and comprehensive analysis.

Authors:  Tian-Liang Ma; Peng Zhu; Jing-Xian Chen; Yi-He Hu; Jie Xie
Journal:  Cancer Gene Ther       Date:  2022-06-28       Impact factor: 5.987

6.  RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis.

Authors:  Xin Yin; Xu Teng; Tianyu Ma; Tianshu Yang; Jingyao Zhang; Miaomiao Huo; Wei Liu; Yunkai Yang; Baowen Yuan; Hefen Yu; Wei Huang; Yan Wang
Journal:  Cell Death Differ       Date:  2022-05-09       Impact factor: 15.828

7.  Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy.

Authors:  Anik Banik; Sheikh Rashel Ahmed; Emran Hossain Sajib; Anamika Deb; Shiuly Sinha; Kazi Faizul Azim
Journal:  Mol Divers       Date:  2021-11-07       Impact factor: 3.364

Review 8.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 9.  Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.

Authors:  Liang Du; Zhifeng Ning; Hao Zhang; Fuxing Liu
Journal:  Chin J Cancer       Date:  2017-03-09

10.  Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer.

Authors:  S Deivendran; Hezlin Marzook; T R Santhoshkumar; Rakesh Kumar; M Radhakrishna Pillai
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.